ArticleMucosal immunology2021
Obeticholic acid ameliorates severity of Clostridioides difficile infection in high fat diet-induced obese mice.
Article in Mucosal immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 34 citations in OpenAlex.
- Phenotypic profiling of neutrophils in acuteGut microbes · 2026Article
- The Bile Acid-Diet-Microbiome Axis inNutrients · 2026Review
- Ecological and dietary strategies to constrain Clostridioides difficile.Cell host & microbe · 2026Review
- Novel bile salt analogs reduce lipid accumulation in liver cells with potential to treat both metabolic dysfunction-associated steatotic liver disease and Clostridioides difficile infection.bioRxiv : the preprint server for biology · 2026Article
- Article
- Diet-Microbiome Analysis in a Healthy Cohort Reveals Potential Role of Intestinal Microbiota in Metabolism.bioRxiv : the preprint server for biology · 2026Article
- Olfactomedin-4Infection and immunity · 2026Article
- High-fat diet rewires gut host-microbiota relationship to derive worse outcomes followingbioRxiv : the preprint server for biology · 2026Article
- Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Impact of Diet on Clostridioides difficile Infection: A Review.The Journal of infectious diseases · 2025Review
- Standard mouse diets lead to differences in severity in infectious and non-infectious colitis.mBio · 2025Article
- Mechanisms ofFrontiers in cellular and infection microbiology · 2025Review
- Shengjiang Xiexin decoction combined with vancomycin forFrontiers in cellular and infection microbiology · 2025Article
- Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria.Frontiers in immunology · 2025Review
- Probing and manipulating the gut microbiome with chemistry and chemical tools.Gut microbiome (Cambridge, England) · 2025Review
- Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections.Pathogens (Basel, Switzerland) · 2024Review
- Gut Microbiota-Gut Metabolites andMetabolites · 2024Review
- Diagnosis and treatment of post-cholecystectomy diarrhoea.World journal of gastrointestinal surgery · 2023Review
- Apple Polyphenol Extract SuppressesMetabolites · 2022Article
- Regulation of intestinal immunity by dietary fatty acids.Mucosal immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Severe Clostridiodes difficile infection (CDI) is life-threatening and responds poorly to treatment. Obesity is associated with development of severe CDI. Therefore, to define the mechanisms that exacerbate disease severity, we examined CDI pathogenesis in high-fat diet (HFD)-fed obese mice. Compared to control mice, HFD-fed mice failed to clear C. difficile bacteria which resulted in protracted diarrhea, weight loss and colonic damage. After infection, HFD-induced obese mice had an intestinal bile acid (BA) pool that was dominated by primary BAs which are known promoters of C. difficile spore germination, and lacked secondary BAs that inhibit C. difficile growth. Concurrently, synthesis of primary BAs from liver was significantly increased in C. difficile-infected HFD-fed mice. A key pathway that regulates hepatic BA synthesis is via feedback inhibition from intestinal Farnesoid X receptors (FXRs). Our data reveal that the proportion of FXR agonist BAs to FXR antagonist BAs in the intestinal lumen was significantly reduced in HFD-fed mice after CDI. Treatment of HFD-fed mice with an FXR agonist Obeticholic acid, resulted in decreased primary BA synthesis, fewer C. difficile bacteria and better CDI outcomes. Thus, OCA treatment holds promise as a therapy for severe CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.